Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
29/12/2025 15:08
Dec 29 (Reuters) - Jiangsu Recbio Technology Co Ltd 2179.HK: NEW DRUG APPLICATION FOR REC610 SHINGLES VACCINE ACCEPTED APPLICATION ACCEPTED BY CENTER FOR DRUG EVALUATION, NMPA Further company coverage: 2179.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares